Akero Therapeutics, Inc.

NASDAQ:AKRO

28.25 (USD) • At close December 27, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) USD.

2024 Q32024 Q22024 Q12023 Q42023 Q32023 Q22023 Q12022 Q42022 Q32022 Q22022 Q12021 Q42021 Q32021 Q22021 Q12020 Q42020 Q32020 Q22020 Q12019 Q42019 Q32019 Q22019 Q12018 Q42018 Q32018 Q22018 Q12017 Q4
Revenue 0000.284000000000000000000000000
Cost of Revenue 00.0010.0010.0020.0050.0690.0680.0650.0660.0650.0640.0630.060.060.0610000000000000
Gross Profit 0-0.001-0.0010.282-0.005-0.069-0.068-0.065-0.066-0.065-0.064-0.063-0.06-0.06-0.0610000000000000
Gross Profit Ratio 0000.993000000000000000000000000
Reseach & Development Expenses 72.23255.32250.6553.39238.63427.98521.78718.3225.08721.36320.51427.71119.4723.97610.60225.70917.37913.0378.79113.13813.8855.964.0631.9831.2538.420.2260.68
General & Administrative Expenses 9.47110.4199.3048.4817.9817.6446.9667.111.0046.2315.5374.7284.8834.994.5264.0744.1593.4173.5883.0832.4241.6491.4490.9850.4740.2420.1950.28
Selling & Marketing Expenses 0-0.001-0.001-0.002000000000000000000000000
SG&A 9.47110.4189.3038.4797.9817.6446.9667.111.0046.2315.5374.7284.8834.994.5264.0744.1593.4173.5883.0832.4241.6491.4490.9850.4740.2420.1950.28
Other Expenses 0-10.4180-16.6267.8445.4033.3792.7230.8730.24400.0150.0230.0330.0380.0720.1350.2470.4930.610.7550.3810.15-58.504-9.421-0.01100
Operating Expenses 81.70365.7459.95361.87146.61535.62928.75325.4236.09127.59426.05132.43924.35328.96615.12829.78321.53816.45412.37916.22116.3097.6095.5122.9681.7278.6620.4210.96
Operating Income -81.703-65.741-59.954-61.873-46.615-35.629-28.753-25.42-36.091-27.594-26.051-32.439-24.353-28.966-15.128-29.783-21.538-16.454-12.379-16.221-16.309-7.609-5.512-2.968-1.727-8.662-0.421-0.96
Operating Income Ratio 000-217.863000000000000000000000000
Total Other Income Expenses Net 8.9989.7546.616.6876.9564.5462.9222.3610.5490.1910.0220.0150.0230.0330.0380.0720.1350.2470.4930.610.7550.3810.15-58.504-9.421-0.01100
Income Before Tax -72.705-55.987-53.344-55.186-39.659-31.083-25.831-23.059-35.542-27.403-26.029-32.424-24.33-28.933-15.09-29.711-21.403-16.207-11.886-15.611-15.554-7.228-5.362-61.472-11.148-8.673-0.421-0.96
Income Before Tax Ratio 000-194.317000000000000000000000000
Income Tax Expense 00-0.042-12.5278.7326.26-2.465-2.574-0.5490.297-0.022-0.011-0.051-0.05-0.05-0.011-0.006-1.323-1.237-0.046-16.309-7.609-5.362-2.9680-8.662-0.4210
Net Income -72.705-55.987-53.344-55.186-39.659-31.083-23.366-20.485-34.993-27.403-26.007-32.424-24.33-28.933-15.09-29.711-21.403-16.207-11.886-15.611-15.554-7.228-5.362-61.472-11.148-8.673-0.421-1.026
Net Income Ratio 000-194.317000000000000000000000000
EPS -1.05-0.81-0.9-0.99-0.71-0.6-0.5-0.44-0.91-0.77-0.74-0.93-0.7-0.83-0.43-0.86-0.63-0.57-0.42-0.55-0.56-2.21-0.2-2.9-0.53-0.41-0.02-4.54
EPS Diluted -1.05-0.81-0.9-0.99-0.71-0.6-0.5-0.44-0.91-0.77-0.74-0.93-0.7-0.83-0.43-0.86-0.63-0.57-0.42-0.55-0.56-2.21-0.2-2.9-0.53-0.41-0.02-4.53
EBITDA -71.458-54.755-52.352-54.287-38.766-30.157-25.306-22.632-35.152-27.285-25.965-32.428-24.27-28.873-15.117-29.772-21.538-16.454-12.379-16.221-16.309-7.6090.15-2.968-11.148-0.081-0.421-0.066
EBITDA Ratio 000-217.856000000000000000000000000